leh kem' bee LEQEMBI

leh kan' uh mab lecanemab

Medication Guide

Prescribing Information

For US residents only
Important Safety
Information
Prescribing
Information
Medication
Guide
Healthcare
Provider Site

For US residents only

Visita el sitio en español

Early
Alzheimer’s
About
LEQEMBI
Getting
started
- What to expect
- Preparing for infusions
Support
& resources
For care
partners
- Supporting your loved one
- Taking care of yourself

Eisai Patient Support
1-833-453-7362
Important Safety
Information
Healthcare Provider Site
LEQEMBI

lecanemab

SEARCH RESULTS

Visita el sitio en español >

NOW FDA APPROVED

Once-monthly (once every 4 weeks) maintenance infusions are available after 18 months. Learn more.
Medicare now covers treatment with Alzheimer's drugs, including LEQEMBI.
Medicare link Medicare link

Medicare now covers treatment with Alzheimer's drugs, including LEQEMBI.
Medicare link Medicare link

AUDREY

living with mild Alzheimer's
dementia,* and her son, Denver

^*

Patient shown is not taking LEQEMBI.
Patient information is accurate as of April 2025.
People featured have been compensated for their time.

SITE MAP

Early Alzheimer’s
What is mild cognitive impairment?
What is early Alzheimer's disease?
Stages of Alzheimer’s disease
Tests you should know about

About LEQEMBI
How does LEQEMBI work?
LEQEMBI study results
Potential side effects
Starting your LEQEMBI conversation

Getting started
What to expect
Preparing for infusions

Support & resources
Insurance & financial support
LEQEMBI Companion™
Downloadable resources
Patient stories
Advocacy organizations
Sign up for more information
Frequently asked questions

For care partners
Supporting your loved one
Taking care of yourself

IMPORTANT SAFETY INFORMATION

WHAT IS LEQEMBI?

LEQEMBI is a prescription medicine used to treat people with early Alzheimer’s disease,
which includes mild cognitive impairment (MCI) or mild dementia stage of disease.

EXPAND COLLAPSE

WHAT IS LEQEMBI?

LEQEMBI is a prescription medicine used to treat people with early Alzheimer’s disease,
which includes mild cognitive impairment (MCI) or mild dementia stage of disease.

WHAT IS LEQEMBI?

LEQEMBI is a prescription medicine used to treat people with early Alzheimer’s disease,
which includes mild cognitive impairment (MCI) or mild dementia stage of disease.

IMPORTANT SAFETY
INFORMATION

What is the most important information I should know about LEQEMBI?

LEQEMBI can cause serious side effects, including:

ARIA (Amyloid-Related Imaging Abnormalities). ARIA is a side effect that does not usually cause any symptoms, but serious symptoms can occur. ARIA can be fatal.

ARIA commonly shows up as temporary swelling in areas of the brain that usually goes away over time
Small spots of bleeding in or on the
surface of the brain can occur
Less often, larger areas of bleeding in the brain can
occur
Most people with ARIA don’t have any
symptoms. However, some people may notice:

– headache

– confusion that gets worse

– dizziness

– vision changes

– nausea

– difficulty walking

– seizures

Some people have a gene called ApoE4 that may increase the risk of ARIA. Talk to your healthcare provider about testing to see if you have this gene
You may be at a higher risk of developing bleeding in the brain if you take medicines to reduce blood clots from forming (antithrombotic medicines) while receiving LEQEMBI. Talk to your healthcare provider to see if any of the medicines you’re taking increase this risk
Your healthcare provider will check for ARIA with MRI (magnetic resonance imaging) scans before you start LEQEMBI and
during treatment
You should carry information that says you are receiving LEQEMBI, which can cause ARIA, and that ARIA symptoms can look like stroke symptoms

Call your healthcare provider or go to the nearest hospital emergency room right away if you have any of the symptoms listed above.

Serious allergic reactions:

Do not receive LEQEMBI if you have serious allergic reactions to LEQEMBI or any of the ingredients in LEQEMBI.

Tell your healthcare provider if you notice any symptoms during or after a LEQEMBI infusion, including:

– swelling of the face, lips, mouth, or tongue

– itchy bumps on the skin,
also known as hives

– difficulty breathing

Infusion-related reactions:

Tell your healthcare provider right away if you notice any of these symptoms during
a LEQEMBI infusion:

– fever

– flu-like symptoms (chills, body aches, feeling shaky, joint pain)

– nausea and/or vomiting

– dizziness or lightheadedness

– fast or slow heart rate, or feeling like your chest is pounding

– difficulty breathing or shortness of breath
If you have an infusion-related reaction, your healthcare provider may give you medicines before your next infusion to lower the chance of having a reaction

The most common side effects of LEQEMBI include infusion-related reactions, ARIA, and headaches.

These are not all the possible side effects of LEQEMBI. Call your doctor for more information
and medical advice about side effects. You may report side effects to the FDA at
www.fda.gov/medwatch or call 1-800-FDA-1088.

Before receiving LEQEMBI, tell your healthcare provider about:

All your medical conditions, including if you are pregnant, breastfeeding, or plan to become pregnant or breastfeed. It is not known if LEQEMBI could harm your unborn or breastfeeding baby
All the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements. Especially tell your healthcare provider if you take medicines to reduce blood clots from forming (antithrombotic medicines, including aspirin)

Please read the full Prescribing Information including Boxed WARNING, and Medication Guide for LEQEMBI.

The health information contained herein is provided for educational purposes only and is not intended to replace discussions with a healthcare provider. All decisions regarding patient care must be made with a healthcare provider, considering the unique characteristics of the patient.

This site is intended for residents of the United States only. The products discussed herein may have different product labeling in different countries. This Website contains information relating to various medical conditions and treatment. Such information is provided for educational purposes only and is not meant to be a substitute for the advice of a physician or other healthcare professionals. You should not use this information for diagnosing a health problem or disease. In order for you to make intelligent healthcare decisions, you should always consult with a physician or other healthcare provider for your, or your loved ones’, personal medical needs. Individual responses to treatment may vary.

About Eisai
Privacy Statement
Site Map
Cookie Preferences
Legal Notices
Facebook

© 2025 Eisai Inc. and Biogen.
LEQE-US4421 June 2025
All trademarks are the property of their respective owners.
LEQEMBI^® is a registered trademark of Eisai R&D Management Co., Ltd.
LEQEMBI Companion^™ is a trademark of Eisai R&D Management Co., Ltd.

You are now leaving LEQEMBI.com.

Eisai Inc. does not endorse the following website, nor does Eisai Inc. review the information contained on the following website for content, accuracy, or completeness.

This site is for US healthcare providers only.

Select “Continue” to verify that you are a US healthcare professional or “Cancel” to return to the previous page.

CONTINUE

You are now leaving LEQEMBI.com.

This tool is developed, hosted, and maintained by NICA, an organization independent from Eisai. Eisai does not control or validate the content on the NICA Infusion Center* Locator website. Eisai is not endorsing or recommending any particular infusion provider by making this link available. The Locator does not provide a comprehensive list of infusion providers, and other infusion providers may be available to patients.

*The NICA Infusion Center serves as a tool to connect patients with the most accessible infusion center in their area, and for providers to find referral sites. Patients should contact the center directly with medication offerings, referral, insurance, scheduling availability, and other site-specific questions.

CONTINUE